Synapse

← Matthias Egger

Papers by Matthias Egger

Page 2 · newest first

  1. Table S7 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  2. Table S8 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  3. Figure 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  4. Table S2 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  5. Table S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  6. Table S13 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  7. Table 2 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  8. Table S2 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  9. Table 3 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  10. Table S12 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  11. Table S12 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  12. Figure S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  13. Table S4 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  14. Table S3 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  15. Figure 2 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  16. Table S3 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  17. Figure 3 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  18. Table S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  19. Table S11 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  20. Table S7 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  21. Table S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  22. Table S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  23. Table S13 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  24. Table S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  25. Table 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study2024
  26. The contribution of non-communicable and infectious diseases to the effect of depression on mortality: a longitudinal causal mediation analysis2024
  27. Predicting emergent Dolutegravir resistance in South Africa: A modelling study2024
  28. Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodiesThe Journal of Experimental Medicine · 2024
  29. Correcting mortality estimates among children and youth on antiretroviral therapy in southern Africa: A comparative analysis between a multi‐country tracing study and linkage to a health information exchangeTropical Medicine & International Health · 2024
  30. Cancer diagnostic service use in people living with HIV in South Africa: A cross-sectional studyPLoS ONE · 2024
  31. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and ZambiaClinical Infectious Diseases · 2024
  32. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 StudyThe Journal of Infectious Diseases · 2024
  33. Protocol for the development of a reporting guideline for umbrella reviews on epidemiological associations using cross-sectional, case-control and cohort studies: the Preferred Reporting Items for Umbrella Reviews of Cross-sectional, Case-control and Cohort studies (PRIUR-CCC)BMJ Open · 2024
  34. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST)2024
  35. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysisThe Lancet Infectious Diseases · 2024
  36. Occupational exposure to benzene and mortality risk of lymphohaematopoietic cancers in the Swiss National CohortScandinavian Journal of Work Environment & Health · 2024
  37. Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort StudyCancer Epidemiology Biomarkers & Prevention · 2024
  38. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration — a Korean translationThe Ewha Medical Journal · 2024
  39. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir TherapyThe Journal of Infectious Diseases · 2024
  40. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIVClinical Infectious Diseases · 2024
  41. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human dataWellcome Open Research · 2024
  42. Air Cleaners and Respiratory Infections in Schools: A Modeling Study Based on Epidemiologic, Environmental, and Molecular DataOpen Forum Infectious Diseases · 2024
  43. Combining randomized and non‐randomized data to predict heterogeneous effects of competing treatmentsResearch Synthesis Methods · 2024
  44. Molecular detection of SARS-CoV-2 and other respiratory viruses in saliva and classroom air: a two winters taleClinical Microbiology and Infection · 2024
  45. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal studyPLoS ONE · 2024
  46. Self-transfers, Hospital Admissions and Mortality Among Children and Adolescents Lost to Follow-up From Antiretroviral Therapy Programs in the Western Cape, South Africa Between 2004 and 2019: Linkage to Provincial RecordsThe Pediatric Infectious Disease Journal · 2024
  47. Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal studyJournal of the International AIDS Society · 2024
  48. The effect of combining antibiotics on resistance: A systematic review and meta-analysiseLife · 2024
  49. The effect of combining antibiotics on resistance: A systematic review and meta-analysiseLife · 2024
  50. Airborne transmission risks of tuberculosis and COVID-19 in schools in South Africa, Switzerland, and Tanzania: Modeling of environmental dataPLOS Global Public Health · 2024